Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies

Anticancer immunotherapies, such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells, have improved outcomes for patients with a variety of malignancies. However, most patients either do not initially respond or do not exhibit durable responses due to primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Kristin G, Braun, David A, Buqué, Aitziber, Gitto, Sarah B, Guerriero, Jennifer L, Horton, Brendan, Keenan, Bridget P, Kim, Teresa S, Overacre-Delgoffe, Abigail, Ruella, Marco, Triplett, Todd A, Veeranki, Omkara, Verma, Vivek, Zhang, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314654/
https://www.ncbi.nlm.nih.gov/pubmed/37399356
http://dx.doi.org/10.1136/jitc-2022-006533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314654/
https://www.ncbi.nlm.nih.gov/pubmed/37399356
http://dx.doi.org/10.1136/jitc-2022-006533

Ejemplares similares